Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | SCD | O00767 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30438937 | 0.83 | PIK3CD (0.40) | PIK3CDTGFBR1DYRK1A | |
| SCHEMBL14896325 | 0.74 | DYRK1A (0.41) | PIK3CDALDH1A1HSD17B10TDP1TNIK | |
| SCHEMBL25259914 | 0.72 | ALDH1A1 (0.36) | PIK3CDALDH1A1HSD17B10TDP1 | |
| SCHEMBL29655527 | 0.72 | EGLN2 (0.41) | PIK3CDALDH1A1TNIKTGFBR1BACE1 | |
| SCHEMBL15739665 | 0.70 | ALDH1A1 (0.42) | PIK3CDALDH1A1HSD17B10TDP1 | |
| SCHEMBL25244964 | 0.70 | NAMPT (0.40) | PIK3CDALDH1A1HSD17B10TDP1SCD | |
| SCHEMBL24167389 | 0.68 | TGFBR1 (0.37) | PIK3CDTNIKTGFBR1BACE1SCD | |
| SCHEMBL619814 | 0.68 | AHR (0.43) | PIK3CDTNIKTGFBR1BACE1SCD | |
| SCHEMBL23432223 | 0.68 | TGFBR1 (0.40) | PIK3CDTNIKTGFBR1BACE1SCD | |
| SCHEMBL29655509 | 0.68 | TGFBR1 (0.46) | PIK3CDALDH1A1TNIKTGFBR1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| EP-4436955-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | Lario Therapeutics Limited (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| EP-2771332-B1 | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | MERCK CANADA INC (CA) | 2016-06-29 | — | — | EP | disclosed |
| EP-2771332-B1 | Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS | MERCK CANADA INC (CA) | 2016-06-29 | — | — | EP | disclosed |
| US-9133157-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-09-15 | — | — | US | disclosed |
| US-9133157-B2 | HIV protease inhibitors | MERCK CANADA INC. (CA) | 2015-09-15 | — | — | US | disclosed |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-10-09 | — | — | US | disclosed |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2014-10-09 | — | — | US | disclosed |
| EP-2771332-A1 | HIV PROTEASE INHIBITORS | Merck Canada Inc. (CA) | 2014-09-03 | — | — | EP | disclosed |
| WO-2013059928-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013059928-A1 | HIV PROTEASE INHIBITORS | MERCK CANADA INC. (CA) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | PIK3CD 2129/4885ALDH1A1 3306/4885HSD17B10 3981/4885 |
| US-20140303171-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, PRSS3 | PIK3CD 2930/4885ALDH1A1 2649/4885HSD17B10 1311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.